BioMAS

Tellurium based Drugs for Autoimmune Diseases

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Technologies
Company Founded Year
Company Number of Employees
BioMAS
Biotechnology & Biopharmaceutical
01/01/2000
"1-10"
Go to company site

BioMAS Ltd is a clinical-stage company focusing on the invention, development, and commercialization of tellurium-based compounds. The company’s lead molecules, AS101 and SAS, are small tellurium-based compounds developed for the treatment of various conditions. The molecules have integrin-inhibitory properties. Integrins are emerging therapeutic targets in many human pathologies.



The company’s AS101/SAS drugs have demonstrated preclinical and clinical safety and efficacy for autoimmune-inflammatory diseases (psoriasis, arthritis, Crohn’s, and MS), certain viral conditions (HPV warts), angiogenesis-related diseases (AMD), thrombocytopenia, neutropenia, and fertility preservation following chemotherapy and radiotherapy.



A 15.4% stake in the company was acquired by Cosmo Pharmaceuticals (XSWS:COPN) for ILS 7 million on March 27, 2014.